Of note, a CRISPR-based screen found NEMO to be among the top 7% of targets for B-cell lymphoma [43], and lymphoid cells do use promoter B for expression of NEMO [19]. This evidence concerns the gene IKBKG and B-cell non-Hodgkin lymphoma.